Shots:

• RedHill has submitted CTA to the MHRA and AIFA for a P-II/III study evaluating opaganib vs PBO along with SOC in patients hospitalized with severe COVID-19. The P-II/III study will enroll 270 subjects in a ratio (1:1) with severe COVID-19 pneumonia requiring hospitalization and treatment with supplemental oxygen
• The company plans to conduct the study in 40+ clinical sites across Russia- Italy- the UK- and additional countries with 1EPs as the proportion of patients requiring intubation and mechanical ventilation by Day 14
• The study follows the ongoing P-IIa study assessing Opaganib in the US and will enroll 40 patients with severe COVID-19 pneumonia requiring hospitalization and supplemental oxygen. Additionally- the company reported the encouraging preliminary findings of the therapy from six COVID-19 patients requiring high-flow supplemental oxygen in Israel under compassionate use

Click here to read full press release/ article | Ref: Buinesswire | Image: RedHill

Related News: RedHill Biopharma Reports the Submission of CTA for P-II/III Study Evaluating Opaganib Against COVID-19 in Russia